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placebo-controlled studies was used to model clinical success
in patients with resistant pathogens. Patients and efﬁcacy rates
were stratiﬁed by severity (mild/moderate;severe) deﬁned as the
number of acute exacerbations (3 and >3) over the last 12
months. Patients could receive up to two treatments in the com-
munity and one hospitalisation. Second-line treatment was based
on German guidelines and expert opinion. Outcomes evaluated
were clinical failure, hospitalisations and second-line treatments
avoided. Resource use and costs were obtained from the trials,
expert opinion and literature. RESULTS: Moxiﬂoxacin domi-
nated all other strategies. Clinical failure rates for moxiﬂoxacin,
beta-lactams and macrolides strategies were 13.1%, 19.1% and
25.3% respectively. Moxiﬂoxacin resulted in a 35% and 58%
reduction in hospitalisation compared with beta-lactams and
macrolides respectively. Results for macrolides and beta-lactams
are affected by lower clinical success rates and higher levels of
resistance for these treatments. Moxiﬂoxacin did not loose its
dominance in any deterministic sensitivity analysis conducted.
CONCLUSIONS: Despite very low overall resistance levels in
Germany, moxiﬂoxacin as ﬁrst line treatment in AECB is a cost-
saving treatment strategy. Even larger economic and clinical
beneﬁts can be expected in countries with higher prevailing resis-
tance rates.
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OBJECTIVES: Budesonide/formoterol (B/F; Symbicort®) mainte-
nance and reliever therapy (SMART) provides superior exacer-
bation control to higher ﬁxed-dose ICS/LABA + SABA at a lower
cost. The cost-effectiveness of increasing the maintenance dose in
SMART is not established. METHODS: In this post hoc
hypothesis-generating analysis, data from two 6-month double-
blind trials of similar design, performed in moderate/severe
asthma populations (mean baseline data: FEV1 70–72% pre-
dicted, ICS 705–740 mg/d), examined the cost-effectiveness of
preventing exacerbations and reducing the percent of uncon-
trolled patients (Asthma Control Questionnaire score1.5) with
B/F 160/4.5 mg bid + prn (Study 1; Kuna et al. Int J Clin Pract
2007) and B/F 2 ¥ 160/4.5 mg bid + prn (Study 2; Bousquet et al.
Respir Med 2007) using 2008 Spanish health care costs. Incre-
mental cost-effectiveness ratios were estimated. RESULTS: The
analysis included 2173 SMART-treated patients. There were 12
exacerbations/100 patients/6 months in each study, and patients
uncontrolled on SMART decreased from 66% to 30% and 62%
to 23% in Study 1 and 2, respectively. Total health care costs
during 6-months of therapy were €366 and €512/patient, respec-
tively. The incremental cost of preventing 3 extra patients in
100 having uncontrolled asthma with high- vs low-dose SMART
was estimated at €4867/patient. CONCLUSIONS: Low-dose
SMART appears to provide unsurpassed exacerbation control
at a low cost but high-dose SMART may achieve better clinical
control in a small minority of patients. These ﬁndings will be
investigated prospectively in >8000 patients in a 6-month study
(EuroSMART) to establish the cost and proﬁle of patients
needing high-dose SMART.
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OBJECTIVES: To explore the short-term cost effectiveness of
Symbicort SMART (using Symbicort Turbuhaler) as compared
with ﬁxed combination therapies (budesonide/formoterol and
salmeterol/ﬂuticasone) with terbutaline as needed in the treatment
of asthma. METHODS: Within the clinical trial economic analy-
sis, Finnish unit costs applied to pooled resource use data and
multinomial cost-effectiveness acceptability curves were formed
based on bootstrapping. RESULTS: Use of Symbicort SMART
signiﬁcantly reduced the rate of severe asthma exacerbations as
compared with ﬁxed dose combinations. The total costs over 6
months were €475 per patient for those who used the Symbicort
SMART treatmentmodel, whichwas €99–107 lower than the cost
of ﬁxed dose combinations. Symbicort SMART treatment model
achieved a very high probability (98.3%) of cost effectiveness.
CONCLUSIONS: Symbicort SMART treatment model should be
considered in the treatment of moderate to severe asthma instead
of conventional treatment with combination products in view
of its good clinical efﬁcacy and a very high probability of cost
effectiveness in the Finnish setting.
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